Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems.

Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems.

Item
http://www.wikidata.org/entity/Q37061029
Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencingCyclin-dependent kinase 11(p110) (CDK11(p110)) is crucial for human breast cancer cell proliferation and growthInhibition of CDK-mediated phosphorylation of Smad3 results in decreased oncogenesis in triple negative breast cancer cells.Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells.Cancer subclonal genetic architecture as a key to personalized medicine.CDK/CCN and CDKI alterations for cancer prognosis and therapeutic predictivity.Dinaciclib for the treatment of breast cancer.Cell-cell and cell-matrix adhesion in survival and metastasis: Stat3 versus Akt.Radionuclide therapy using ¹³¹I-labeled anti-epidermal growth factor receptor-targeted nanoparticles suppresses cancer cell growth caused by EGFR overexpression.A Versatile Cell Death Screening Assay Using Dye-Stained Cells and Multivariate Image AnalysisSequential combination of flavopiridol with Taxol synergistically suppresses human ovarian carcinoma growth.Potential Use of Flavopiridol in Treatment of Chronic Diseases.Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro.Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems.Activation of CDK4 Triggers Development of Non-alcoholic Fatty Liver Disease.
P2860

Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems.

Item
http://www.wikidata.org/entity/Q37061029
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Flavopiridol synergizes with s ...... F breast cancer model systems.
@en
Flavopiridol synergizes with s ...... F breast cancer model systems.
@nl
type
label
Flavopiridol synergizes with s ...... F breast cancer model systems.
@en
Flavopiridol synergizes with s ...... F breast cancer model systems.
@nl
prefLabel
Flavopiridol synergizes with s ...... F breast cancer model systems.
@en
Flavopiridol synergizes with s ...... F breast cancer model systems.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921
P932
P356
P1433
P1476
Flavopiridol synergizes with s ...... F breast cancer model systems.
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921
P932